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Rare disease definition varies among countries/regions. China has published The First 
National List of Rare Diseases, including 121 kinds of rare diseases in 2018. It was the first 
time that China has defined rare diseases officially. China has also started releasing a range of 
encouraging regulations regarding orphan drug development and approval in recent years. 
Nevertheless, the FDA has introduced Orphan Drug Act in the 1980s, Japan has launched a 
government-led support initiative in the 1990s, and the European Parliament has adopted the 
Orphan Regulation in 2000. Among the 121 rare diseases, 58 of them have approved 
treatments in the US, the EU, or Japan, with 124 drugs in total. Until 2020, only 68 drugs 
have been approved in China, meaning many remaining rare diseases have no treatment yet in 
China, and there is still a long way to go for orphan drug approval. Also, as orphan drugs 
usually have dramatically high prices, being listed in the National Reimbursement Drug List 
(NRDL) would help decrease the economic burden for patients significantly. However, 
among the 68 approved drugs, only 38 have been included in the NRDL. This study showed 
that successful orphan drug approval in China is associated with two significant 
characteristics, registration status in the National Rare Diseases Registry System, and the 
sponsor size. Orphan drug reimbursement is associated with orphan drug substances. The 
information may help drug developers and regulators in future orphan drug market access 
programs in China. 
Keywords: Rare disease, Orphan drug, drug approval, drug reimbursement, 
Department of Chronic Disease Epidemiology  
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3 million 30 million /a /a /a 
Number of 
rare diseases b 
>7000 6000-8000 123 121 261 
a / means no data available  
b Number of rare disease patients in total and number of rare diseases are estimated numbers 
 
Table 2. Current effective national policies about rare diseases since 2015 
Effective time Policy & regulation (official 
titles a) 
Contents about rare disease 
2015 Opinions of the State Council 
on Reform of the System of 
Evaluation, Review and 
Approval of Drugs and 
Medical Devices 
21 
Accelerated evaluation and 
approval process for treatment 
of rare diseases 
2017 Opinions on Deepening the 
Reform of the Evaluation and 
Approval Systems and 
Encouraging Innovation on 
Drugs and Medical Devices22 
Establishing rare disease 
patient registration system in 
China 
Reduced number or exempting 
clinical trials application could 
be submitted, and the Center 
for Drug Evaluation (CDE) 
would make evaluation opinion 
based on the actual situation of 
the Chinese patients 
Orphan drugs that have been 
approved overseas may be 
approved conditionally. The 
sponsor shall be responsible for 
risk management and  
research as required  
2018 Announcement on Matters 
Concerning the Optimization 
Orphan drugs that do not have 
ethnic disparities after research 
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of Drug Registration Review & 
Approval23 
could be approved by 
submitting overseas clinical 
trial data  
2018 First Official Chinese Orphan 
Drug List9 
121 recognized rare diseases 
2018 Announcement on Matters 
Related to Clinical Urgent 
Needed for Overseas New 
Drug Review and Approval 24 
Drug approval evaluation 
should be completed within 
three months for listed orphan 
drugs (six-month for non-
orphan drugs) from the 
reception of the dossiers. 
The National Medical Products 
Administration (NMPA) must 
deliver the examination and 
approval decision within ten 
days after receiving the review 
outcomes from CDE (20 days 
for other drugs that are not 
urgently needed)  
2018 List of Urgently Needed New 
Drugs in Clinical Settings (the 
first batch)25 
The second batch of the 
Urgently Needed Drugs in 
Clinical Settings was published 
in 201926 
The third batch of the Urgently 
Needed Drugs in Clinical 
Settings was published in 
202027 
Including 34 orphan drugs in 
total 
2019 Announcement of Reducing 
Import Tariffs on Drugs26 
The added value tax for 21 
orphan products and 4 active 
pharmaceutical ingredients was 
reduced from 16% to 3% upon 
import 
2020 Evaluation and Approval for 
Breakthrough Therapies27 
Accelerated approval of 
innovative therapies which 
possibly have beneficial 
outcomes based on first and 
second stages clinical trial 
evidence 
a English translation of these policy titles are from the Chinalawinfo database18 
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Table 3. Variable category, specific characteristics, inclusion criteria, and data sources of orphan drugs 





Inclusion criteria and data sources  
Characteristic 
related to the drug 
substance 
Small molecule or 
biologics  
Small molecule has a low molecular weight (<900 
Da)42,50 
Molecule been used 
for other indications  
Data collected through several open 
databases41,42,43,44,45 
Characteristics 
related to the 
indication 
Indication category The indications were classified as cardiovascular and 
respiratory, endocrinology and metabolic, hematology, 
immunology, infectious diseases, musculoskeletal and 
nervous system, oncology, and Other2. 
Since each of the indication category of the drugs 
comprised a small proportion of the total dataset, they 
were grouped together when doing regression 
analysis.  
Multiple drugs 
available on the 
market 
Data collected through several open 
databases41,42,43,44,45 
Registration data 
available in NRDRS 
The National Rare Diseases Registry System of China 
(NRDRS)40 has started registering rare disease patients 
since 2019. However, the system uses a broader list of 
rare diseases (i.e., the system has registered more rare 
diseases than the original list of 121 kinds), 166 kinds 
of diseases have registered patients, with 63301 
patients have already been registered in total. 
Prevalence data 
available in the 
Chinese population 
The prevalence of the diseases in China was collected 
from the Rare Disease Guidelines51,52 published by 
National Health Commission. 
However, some diseases do not have available 
prevalence data in China, then Asia or worldwide data 
were used instead3,51. Also, not every epidemiology 
study has done national-wide research. Many of them 
were only done in partial regions in certain countries, 
so the prevalence data may not represent the true rate. 
Prevalence The prevalence was classified as less than 5 per 
100,000, 5-10 per 100,000, and more than 10 per 
100,0002. 
Characteristics 
related to the 
prior approval 
status 
Number of regions 
that have given the 
drug marketing 
authorization 
Some drugs have received marketing authorization 
from more than one country/region among the 
US/EU/Japan. 




in any country 
Some drugs have received Orphan Designation before 
in the US/EU/Japan. 
Both the drug and disease or condition must meet 
certain criteria set by the Orphan Drug Act and FDA’s 
regulation to receive the orphan status in the US53. 
Similar in the EU, drugs can receive such designation 
if meeting the criteria made by EMA54. 
Data collected through several open 
databases41,42,43,44,45 
Characteristics 
related to the 
sponsor 
Sponsor nationality The sponsor information was collected from the 
mentioned databases41,42,43,44,45 and official websites 
of each company. 
Company regions are classified as the USA, the EU 
(including UK and Switzerland), Japan, and others 
(including Korea, Hongkong, Israel, Australia, and 
Canada). 
Sponsor size (number 
of employees) 
A company with 0-100 employees is considered a 
small-size business, with 100-999 employees is 
considered a medium-sized business, with 1000-9999 
employees is considered a large-sized business, and 
more than 10,000 employees are considered top-large 
companies55.   
Yet some drugs were claimed specifically from a 
certain bureau of the global company, then the size of 
the company was also adjusted to the size of the 
certain bureau. 
Experience in orphan 
drug development 
Different countries have defined orphan drugs 
differently, so the definition of orphan drugs used in 
the data analysis section is the 124 drugs targeting 
diseases from CRDL. 
 
Table 4. Association between determinants and having available orphan drugs in China (univariate and 
multivariate regression analysis) 
Characteristic Total 
(n=58) 










Multiple drugs available on the market    
No 36(62.1) 15(41.7) 1.00 N/Ab 
Yes 22(37.9) 14(63.6) 2.45(0.82, 7.30) 
Registration data available in NRDRS 
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No 40(67.0) 15(37.5) 1.00 1.00 
Yes 18(31.0) 14(77.8) 5.83(1.62,21.03) 5.83(1.62,21.03)a 
Prevalence data available in the Chinese population 
No 42(72.4) 18(42.9) 1.00 N/Ab 
Yes 16(27.6) 11(68.8) 2.93(0.87,9.94) 
Prevalence  
<5 per 100,000 41(70.7) 17(41.5) 1.00 N/Ab 
5-10 per 100,000 7(12.1) 5(71.4) 3.53(0.61,20.38) 
>10 per 100,000 10(17.2) 7(70.0) 3.29(0.74,14.59) 
a the result of the univariate regression and multivariate are identical because this is the only variable 
left after the backward elimination 
b N/A, not applicable after the backward elimination of the multivariate analysis 
 
Table 5. Association between determinants and orphan drugs approval status in China (univariate and 
multivariate regression analysis) 
Characteristic Total  
(n=124) 








No 52(41.9) 28(53.9) 1.00 N/Aa 
Yes 72(58.1) 40(55.6) 1.07(0.52, 2.19) 
Molecule been used for other indications before 
No 85(68.6) 49(57.7) 1.00 N/Aa 
Yes 39(31.5) 19(48.7) 0.70(0.33, 1.49) 
Number of regions that have given the drug marketing authorization 
1 67(54.0) 32(47.0) 1.00 1.00 
>=2 57(46.0) 36(63.2) 1.88(0.91, 3.86) 1.99(0.89, 4.46) 
Orphan designation in any country 
no 25(20.2) 16(64.0) 1.00 N/Aa 
yes 99(79.8) 52(52.5) 0.62(0.25, 1.54) 
Sponsor nationality 
Other  6(4.8) 4(66.7) 1.00 N/Aa 
USA 67(54.0) 31(46.3) 0.43(0.07, 2.51) 
EU 47(37.9) 30(63.8) 0.88(0.15, 5.33) 
Japan 4(3.2) 3(75.0) 1.50(0.09, 25.39) 
Sponsor size (number of employees) 
<100 16(12.9) 2(12.5) 1.00 1.00 
100-999 30(24.2) 16(53.3) 8.00(1.54, 41.49) 8.64(1.63, 45.69) 
1000-10,000 35(28.2) 20(57.1) 9.33(1.84, 47.44) 8.07(1.56, 41.68) 
>10,000 43(34.7) 30(69.8) 16.15(3.20, 81.48) 16.75(3.27, 85.88) 
Experience in orphan drug development  
No 41(33.1) 19(46.3) 1.00 N/Aa 
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Yes 83(66.9) 49(59.0) 1.67(0.79, 3.55) 
a N/A, not applicable after the backward elimination of the multivariate analysis 
 
Table 6. Association between determinants and being included into NDRL in China (univariate and 
multivariate regression analysis) 
Characteristic Total 
(n=68) 









No 28(41.2) 8(28.6) 1.00 1.00 
Yes 40(58.8) 30(75.0) 7.50(2.53, 22.27) 7.50(2.53,22.37)a 
Molecule been used for other indications before 
No 49(72.1) 27(55.1) 1.00 N/Ac 
Yes  19(27.9) 11(57.9) 1.12(0.38, 3.27) 
Number of regions that have given the drug marketing authorization 
1 32(47.1) 21(65.6) 1.00 N/Ac 
>=2 36(52.9) 17(47.2) 0.47(0.18, 1.25) 
Orphan designation in any country 
No 16(23.5) 12(75.0) 1.00 N/Ac 
Yes 52(76.5) 26(59.0) 0.33(0.10, 1.17) 
Sponsor nationality 
Other  4(5.9) 1(25.0) 1.00 N/Ac 
USA 31(45.6) 15(48.9) 0.70(0.13, 3.68) 
EU 30(44.1) 19(63.3) 1.30(0.24, 6.89) 
Japan 3(4.4) 3(100.0) N/Ab 
Sponsor size (number of employees) 
<100 2(2.9) 2(100.0) N/Ab N/Ac 
100-999 16(23.5) 7(43.8) 1.00 
1000-10,000 20(29.4) 8(40.0) 0.67(0.18, 2.41) 
>10,000 30(44.1) 21(70.0) 2.33(0.70, 7.82) 
Experience with orphan drug development  
No 19(27.9) 13(68.4) 1.00 N/Ac 
Yes 49(72.1) 25(51.0) 0.48(0.16, 1.47) 
a the result of the univariate regression and multivariate are identical because this is the only variable 
left after the backward elimination 
b N/A, not applicable (deleted because of quasi-complete separation) 
c N/A, not applicable after the backward elimination of the multivariate analysis 
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reimbursement in China by comparing orphan drugs approved and reimbursed to those 
approved but not reimbursed.  
Previous studies done in other countries have shown drug characteristics associated with 
successful approval of orphan drugs, including characteristics related to indications, 
characteristics related to drug substance, characteristics related to prior approval status, and 
characteristics related to the sponsor1,2,3. However, no existing studies have analyzed the 
characteristics and determinants of the approved and the National Reimbursement Drug List 
(NRDL) listed orphan drugs in China. The US, the EU, and Japan are mainly used for 
reference and comparison. These are countries/regions that are more experienced in orphan 
drug development and approval, and they are the leading pharmaceutical markets in the 
world3. This study would provide information for drug developers and regulators in China in 
future orphan drug market access projects by accomplishing these objectives. 
 
Background introduction and policy review 
Rare disease definition 
Rare diseases are generally severe, chronic, and life-threatening, and 80% of rare diseases are 
generic origins4, yet the definition varies across countries and regions, as shown in Table 1.  
China did not have an exact definition of rare diseases until May 2018. In 2018, China 
National Health Commission, Ministry of Science and Technology, Ministry of Industry and 
Information Technology, National Medical Product Administration, and National 
Administration of Traditional Chinese Medicine had co-posted the First National List of Rare 
Diseases (hereinafter referred to as China Rare Disease List, CRDL)9, included 121 kinds of 
 12 
diseases. The definition of rare diseases in China remained controversial before the 
establishment of the CRDL. They were defined as diseases with prevalence less than 
1/500,000 or neonatal morbidity of less than 1/10,000, as recommended by the Genetics 
Branch of the Chinese Medical Association11. The current CRDL is based on actual 
conditions of diseases, derived from opinions of the Expert Committee on the Diagnosis, 
Treatment, and Care for Rare diseases12. Like Russia, both countries are “disease-centered” 
by directly defining a list of diseases13. The Russian rare disease list was published in Federal 
Law on the Foundation of Health Protection in Russia in 201110. The list consisted of three 
categories of rare diseases, including rare diseases that are extremely expensive to treat and 
are uniformly purchased by the federal government; life-threatening diseases; and common 
rare diseases10,13. Though no study or explanatory document clarifying how China identified 
the CRDL exactly, it is suggested China has referred from Russia to define rare diseases13. In 
conclusion, publication of the CRDL would be expected to help in the management of rare 
disease patients. The CRDL would be also be used as a reference by government agencies and 
ministries12.  
 
Orphan drug overview 
Orphan drugs treat rare diseases and conditions, yet not all of the rare diseases have adequate 
medication4. The FDA has introduced the Orphan Drug Act in 19835, Japan launched a 
government-led support initiative in 1993 about orphan drug designation14, and the European 
Parliament has adopted Regulation (EC) No 141/2000 (the Orphan Regulation) in 200015. All 
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these programs had the purpose of promoting pharmaceutical companies to develop drugs for 
rare diseases through both the regulatory and economic incentives13. 
European Medicines Agency (EMA) has authorized over 160 orphan medicines since 200016. 
FDA has approved more than 770 orphan medicines since 198317. Japan has approved more 
than 300 orphan drugs18. 
It was not until recent years that China has started releasing a range of encouraging 
regulations regarding orphan drug development and approval. Until 2020, among the 121 rare 
diseases, 58 of them have approved treatments in the US, or the EU, or Japan. 124 drugs are 
used to treat the 58 diseases, and 68 of 124 drugs have been approved in China. This means 
many remaining rare diseases have no treatment yet in China, and there is still a long way to 
go for orphan drug approval13.  
 
Orphan drug policy progress in China 
In the 2010s, it has been proposed several times from the national level to address the 
importance of universal health care. In 2015, Healthy China 2030 Planning Outline19 was 
published officially by China’s Central Party Committee and the State Council, which was the 
first strategic plan in the health sector since the founding time of PRC. This means health has 
been put at the center of the entire policymaking machinery in China20. 
Since 2015, several regulations have been promoted to incentivize orphan drug development 
and approval, as shown in Table 2. It is worth noting that the official CRDL was not 
published until 2018, so rare disease definition before 2018 mentioned in any regulations was 
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based on the recommended definition by the Genetics Branch of the Chinese Medical 
Association11. 
In summarization, these policies focus on 1. The accelerated approval process for orphan 
drugs, i.e., shorter evaluation time than non-orphan drugs; 2. Conditional approval for orphan 
drugs from overseas without all-stage clinical trial data; 3. Tax credits for imported orphan 
drugs.  
These policies share many common points with the policies of some other countries. 
Particularly, the US, as the first country to officially promulgate orphan drug legislation, and 
as the leading pharmaceutical market globally, it has already formed a complete set of 
incentive policies and approval procedures29. Therefore, China has borrowed many 
experiences from the US29. The Orphan Drug Act has created incentives, including 1. A 7-
year market exclusivity period for orphan drugs; 2. Tax credits for drug development 
spending; 3. Financial aid for drug research and development; 4. Fast-track development and 
approval pathway (“a process to facilitate development and expedite the review of drugs to 
treat serious conditions and fill an unmet medical need”30); 5. Waiver for drug application 
fees; and 6. Investigational New Drug Program and pre-approval pathway31. Comparing these 
two regulatory systems, we could tell that both regulatory systems have focused on the 
accelerated approval process and tax incentives. However, they two still vary in several 
aspects. Instead of focusing more on incentives for research, China pays more attention to 
providing convenience for drug importation from overseas. This could be because most drugs 
are developed originally overseas13. Specifically, the US has provided market exclusivity for 
orphan drug developers, tax credits for development fees and research grants. In contrast, 
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China has provided tax credits for imported orphan drugs, and reduced or exempting clinical 
trials when importing orphan drugs. 
However, in 2018, CDE has published Implementation Measures for the Protection of Drug 
Test Data (draft for Solicitation of Comments)32, exploring possibilities of providing data 
exclusivity period of 6 years for innovative drugs and 12 years for innovative biologics in the 
near future. This policy has not been officially approved, yet it acted as an essential sign of 
incentivizing future domestic new drug R&D in China in the future32. 
 
The payment system in China 
In China, public insurance covers over 90% of medical insurance, including national and 
provincial level13, yet huge disparities remain in coverage scope and depth. Three insurance 
schemes exist, including insurance for rural residents, insurance for unemployed urban 
residents, and insurance for urban employed residents33. Urban employed residents have far 
more resources than the other two kinds of residents33. Also, covered scope, co-payment 
levels, deductibles, and reimbursement ceiling vary hugely. Even within the same scheme, 
coverage extent would rely on local financial support. Generally, even though public medical 
insurance coverage has increased to 95% of the general population, there is a long way to go 
to reach free medication33. 
Though many orphan drugs have dramatically high value, covering orphan drugs to national 
and local reimbursement funds could be feasible34. A study estimated that orphan drug 
expenditure would only account for 0.5%-2% of the country’s overall medical insurance 
budget, which could be considered controllable34.  
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Some cities in China have pioneered exploring medical insurance for rare disease patients, yet 
these policies still have revealed some underlying issues. Qingdao city has started digging a 
payment system in 2005. First, the officials of Qingdao city would negotiate with 
manufacturers to get a price reduction in drugs. Second, the government funds would 
guarantee the bulk in the payment, while patients take a small amount of cost-sharing. Third, 
the remaining part would be covered by charity funds from the donation of pharmaceutical 
companies and the whole society35. However, such local policies have exacerbated the 
inequality in distributing public health resources13.  
Another remaining issue is the lack of systematic and concrete design of the whole payment 
system. Even in Shanghai, the leading city in exploring the orphan drug payment system, 
charity NGOs and the local government are still disjointed. The patient information of the two 
systems could not be connected and transferred in time. Problems such as repeated 
reimbursement both by the government and social charity funds are prone to occur. Also, 
different functional departments have not yet formed clear boundaries of the rights and 
responsibilities13. 
Furthermore, both Qingdao and Shanghai still highly rely on the motivation of individuals, 
not by the government36. In the future, we should be expecting a reform coming down from 
the national level to form a more comprehensive system13,36. 
In general, national legislation should be developed more quickly to satisfy the emerging need 
for orphan drug access. Luckily, in more recent years, more and more orphan drugs have been 
taken into the National Drug Reimbursement list13,34. Hopefully, as promoted by the National 
People’s Congress members, all drugs targeting the CDRL will be reimbursed eventually37.  
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Possible accessibility barriers  
Besides high prices, some other factors have also decreased accessibility. 1. In hospitals, the 
total number of drugs, the total amount of medical insurance budget used, and drug sales as a 
share of the total revenue are all under control. Although these policies were originally 
intended for health care spending control, public hospitals may hesitate in purchasing orphan 
drugs due to these restrictions13; 2. Physicians’ prescriptions are also restricted, because they 
are also under such control. They might be very cautious about their prescriptions13; 3. Most 
rare diseases do not require long-term inpatient treatment. Patients mostly rely on outpatient 
visits13. However, outpatient reimbursement is limited and has complicated restrictions; 4. 
Due to the limited number rare disease patients, especially in smaller cities, local hospitals are 
unlikely to offer orphan drugs. Not every patient could afford the traveling fee to larger cities 
for treatment13,34. 
In general, China has also started increasing the accessibility and affordability of orphan 
drugs. Nevertheless, it is currently still at the stage of expanding coverage, instead of focusing 
more on further cost control, but it is expected that price reduction and cost control are the 
next steps13. 
 
Possible determinants of orphan drug approval 
Previous studies have been done in the US, the EU, and Japan, looking at determinants for 
orphan drug approval. 
A study in the US1 has concluded that sponsor size and sponsor experience in orphan drug 
development have shown clear associations with orphan drug approval. Small and medium 
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companies have shown a higher probability of rejection1. Also, less experienced companies in 
orphan drug development might face extra challenges when designing and conducting clinical 
trials, such as statistical design challenges due to limited patient numbers, and difficulty in 
recruiting a sufficient number of participants38. Besides, this study indicated that new 
molecules that have never been used in any other clinical practice have an eightfold higher 
chance of non-approval1. 
Another study done in the EU2 has found that oncological and metabolic-related products 
have a higher chance of receiving marketing authorization. Also, drugs been previously used 
in other countries were more likely to be approved in the EU. Besides, small molecule 
products were more likely to receive marketing approval than biologics due to safety 
concerns. Also, in EU, the urgent and high medical need seems to be considered to be more 
important than scientific evidence due to a clear association between lack of alternative 
therapy and successful approval2. 
In Japan, 74.4% of orphan products have already been previously approved in other 
countries/regions, such as the US39. Another analysis33 also showed that successful orphan 
drug development in Japan was associated with prior approval status in the US. Besides, some 
other factors were also positively associated with successful marketing approval, such as 
sponsor size, sponsor experience in orphan drug development, and unmet clinical needs 3. 
In conclusion, variables that are considered related to marketing approval include 1. 
Characteristic related to the drug substance, including whether it has been used in other 
clinical therapies before, and small molecule or biologics; 2. Characteristics related to the 
indication, including registration status in the National Rare Diseases Registry System of 
China (NRDRS)40, indication category, disease prevalence and existing epidemiology studies 
in China, and alternative treatments availability for the disease; 3. Characteristics related to 
prior approval status, including prior approval status in other countries/regions, and whether it 
has received orphan designations in other countries/regions; 4. Characteristics of the sponsor, 
including the company nationality, company size, and prior experience with orphan drug 
development1,2,3,7,13.  
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Thus, this study is going to 1. Summarize characteristics of the approved orphan drugs in 
China, and those that have not been approved yet (the drugs that have been approved 
successfully in other countries/regions, yet not approved yet in China), using characteristics 
mentioned above; 2. Find determinants for orphan drug approval in China in comparing 
orphan drugs that have been approved elsewhere in the world but not in China with China- 
approved ones, and 3. Find determinants for orphan drug reimbursement in China by 
comparing orphan drugs approved and reimbursed to those approved and not reimbursed.  
 
Methods  
Data collection  
The list of the 121 kinds of rare diseases was derived from the National Health Commission1. 
Available treatments targeting the 121 diseases are derived from the US/EU/Japan drug 
approval data in several open data bases41,42,43,44,45. Drugs that are only recognized as on-label 
use for specific indications have been included in the analysis, i.e., if a drug that was only 
approved to treat disease A but was prescribed by physicians to treat rare disease B off-label, 
was not included in the dataset48. Also, only drugs that have received marketing authorization 
in the US/EU/Japan, i.e., have been officially registered, were included in the analysis49. The 
inclusion criteria have yielded 124 drugs in total, targeting 58 diseases as of March 2021. 
The choice of study variables was based on the analysis of past relevant studies1,2,3, including 
four major categories mentioned in the last section. Table 3 shows detailed inclusion criteria 
and data sources. 
The list of orphan drugs which have been listed in the NDRL was obtained from the official 
National Drug Catalog for Basic Medical Insurance, Work-Related Injury Insurance, and 
Maternity Insurance (2020 Edition)56, which included 38 orphan drugs. 
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Data analysis  
This study has done three sets of comparisons. The first one was to compare diseases that 
currently have available drugs in China and those do not yet. Explanatory variables used are 
characteristics related to the indication. The second one was to compare the characteristics of 
orphan drugs currently available in China and those not yet. Explanatory variables used are 
characteristics related to drug substance, the prior approval status, and the sponsors. The third 
comparison was made between drugs that in the NDRL and those that do not, using the same 
variables mentioned above in the second comparison group.  
Univariate regression was conducted first. Multivariate logistic regression analysis was done 
at the next step. The backward elimination strategy was used to derive the most parsimonious 
model. All the independent variables are entered into the equation first, and the least 
significant variable will be deleted at each step57. The reason for choosing this strategy is that 
the number of variables is smaller than the sample size, and the full model gives us the chance 
to consider the effects of all variables simultaneously first58. Both the odds ratios (OR) and 
95% confidence intervals (95% CI) were calculated in both models. SAS (SAS 9.4 TS1M5, 
Rev. 940_18w08) is used in the analysis process. 
 
Results 
The market status of therapeutic drugs for rare diseases in the CRDL is displayed in Figure 1. 
Out of the 121 diseases, 58 of them have therapeutic drugs (in the US/EU/Japan). 124 drugs 
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are available for the 58 kinds of diseases. 68 of 124 drugs are available now in China, 
targeting 29 diseases. 38 of 68 drugs have been reimbursed, targeting 16 diseases. 
 
Determinants for orphan drug approval in China 
Characteristics related to the indication  
The Proportion of approved and non-approved orphan drugs in China per indication category 
is displayed in Figure 2. 12 of 26 drugs for endocrinology and metabolic diseases have been 
approved. By contrast, only 1 of 8 drugs for immunology diseases have been approved. The 
result has revealed a similar outcome with the EU study2. None of the 58 diseases are 
classified as oncology or infectious diseases. This may be because that only one oncology 
disease is included within the CRDL (Retinoblastoma), and no infectious disease is within 
CRDL.  
Descriptive statistics of the 58 rare diseases that have available orphan drugs are displayed in 
Table 4. 62.1% (36 of 58) diseases only have one available in-label treatment. For example, 
Idiopathic Pulmonary Arterial Hypertension has 11 on-label drugs, and hemophilia has 12 on-
label drugs, and both of them have more than one approved drug in China. The reason why 
these diseases have multiple treatments could because, for example, drugs for pulmonary 
hypertension are not a cure for the disease, they help improve symptoms and slow disease 
progression. The mechanisms of these drugs vary59. As for the treatment of hemophilia, 
clotting factor concentrates could be injected into a person’s vein to replace the missing blood 
clotting factor, so there is more than one choice of such concentrates60.  
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The NRDRS40 data showed that only 31% (18 of 58) of them have registered data in the 
system, consisting of over 60,000 cases in total. Yet 77.8% (14 of 18) of diseases with 
registered data in the system have treatment currently available in China. The 18 diseases are 
Fabry disease, Gaucher’s disease, Glycogen Storage Disease (Type I, II), Wilson Disease, 
Hereditary Angioedema, Homozygous Hypercholesterolemia, Hyperphenylalaninemia, 
Idiopathic Pulmonary Arterial Hypertension, Mucopolysaccharidosis, Multiple Sclerosis, 
Generalized Myasthenia Gravis, Tuberous Sclerosis Complex, Leber Hereditary Optic 
Neuropathy，hemophilia, Porphyria, Retinitis Pigmentosa, Langerhans Cell Histiocytosis, 
and Lymphangioleiomyomatosis. Clearly, the number of rare disease patients is much greater 
than 60,000 in China, so more disease and patient data should be expected to be registered in 
the system in the future.  
Only 27.6% (16 of 58) of the diseases have existing epidemiology studies in Chin. 70% (41 of 
58) of the diseases have prevalence less than 5 per 100,000. 
The outcome of the logistic regression is also presented in Table 5. Having registered patients 
in the NRDRS seems to be highly positively correlated with available treatments in China 
(OR=5.83; 95%CI=1.62-21.03), and this result is statistically significant, even after the 
multivariate analysis. 
The other associations are not considered statistically significant yet may suggest possible 
relationships. Diseases that have multiple alternative therapies worldwide are numerically 
more likely to have approved drugs in China (OR=2.45; 95%CI=0.82-7.30), i.e., diseases 
with several available treatment plans are more likely to also have treatment plans in China. 
Diseases that have higher prevalence are numerically more likely to have available treatments 
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in China, 5-10 per 100,000 has an OR of 3.53 (95%CI=0.61-20.38), >10 per 100,000 has an 
OR of 3.29 (95%CI=0.74,14.59). Also, 68.8% of diseases with epidemiology studies done in 
China have available treatments in China, with an OR of 2.93 (95%CI=0.87-9.94). 
In conclusion, having an exact number of registered patients in the NRDRS may be highly 
correlated with approving treatments in the Chinese population.  
 
Characteristics related to the orphan drug substance 
Descriptive statistics of the 124 orphan drugs targeting rare diseases from the CRDL are 
displayed in Table 5. Among all the 124 drugs, only 68 are currently approved for on-label 
use in China. 58.1% (72 of 124) of them are small molecule drugs. 68.6% (85 of 124) are 
used as the only on-label product for certain diseases. 
According to the unadjusted model, small molecule and biologics have a numerically similar 
chance of approval (OR=1.07, 95%CI=0.52-2.19). Molecules that have also been used for 
other indications are numerically less likely to be approved (OR=0.7, 95%CI=0.33-1.49), yet 
both correlations are not considered statistically significant. 
 
Characteristics related to the prior approval status 
As shown in Table 5, 43.5% (54 of 124) of them have received marketing authorization in 
more than one country/region. 79.8% (99 of 124) of the drugs have received orphan 
designation in at least one of the regions mentioned above. 
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Regression analysis suggests drugs that have marketing authorization in more than one 
country/region are numerically more likely to be approved (ORadj=1.99, 95%CI=0.89-4.46), 
though the p-value is greater than 0.05 (p-value=0.074).  
 
Characteristics related to the sponsor  
As shown in Table 5, 54.0% (67 of 124) of the drugs were sponsored or developed by 
American companies, 37.9% (47 of 124) were from EU sponsors, the rest few were from 
companies of some other countries/regions, including Japan, Korea, Canada, and Israel. 
34.7% (43 of 124) of the companies have employees over 10,000 worldwide, such as Pfizer, 
Novartis, Novo Nordisk, Eli Lilly, etc. While 12.9% (16 of 124) companies are small-sized 
businesses, with employees worldwide less than 100 people, such as Immedica Pharma, 
Recordati Rare Disease, Lucane Pharma, etc. 
The outcome of the regression analysis is also shown in Table 5. Companies with more than 
10,000 employees are more likely to have drugs approved (ORadj=16.75, 95%CI=3.27-
85.88). Also, medium-sized and large companies are both more likely to have drugs been 
approved than small-size companies, yet less likely than top-sized companies.  
The other two associations are not considered statistically significant. Drugs that are from the 
US sponsors (OR=0.46, 95%CI=0.08-2.66) seem numerically less likely to be approved than 
from EU (OR=0.82, 95%CI=0.14-4.99) or Japan (OR=1.50, 95%CI=0.09-25.39) sponsors. 
Companies which have developed orphan drugs before are numerically more likely to have 
drugs been approved (OR=1.67, 95%CI=0.79-3.55).  
 
 25 
Determinants for orphan drug reimbursement in China 
Among all the 68 approved drugs, 38 of them have already been included in the NDRL. 
Descriptive statistics of the 38 orphan drugs are displayed in Table 6. 
 
Characteristics related to the orphan drug substance 
58.8% (40 of 68) of them are small molecules. 72.1% (49 of 68) of them have not been used 
before for any other in-label indications. 
The outcome of regression analysis is also shown in Table 6. Small molecules are considered 
more likely to be included to the NDRL (OR=7.5, 95%CI=2.53-22.37). The multivariate 
analysis confirmed that small molecule is the only factor associated with being included in 
NDRL statistically significant. Drugs that have been used before for other indications have 
shown a slightly numerically positive correlation with been included in the NDRL, yet this 
correlation is not considered statistically significant (OR=1.12, 95%CI=0.38-3.27). 
 
Characteristics related to the prior approval status 
52.9% (36 of 68) of them have received marketing authorization from more than one 
region/country. 76.5% (52 of 68) have received orphan designation before in other 
regions/countries.  
The two associations are not considered statistically significant, as shown in Table 6. Having 
orphan designation is considered numerically negative correlated with been included in 
NDRL (OR=0.47, 95%CI=0.18-1.25). Though this correlation is not statistically significant, it 
has revealed the same trend with factors associated with approval. 
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Characteristics related to the sponsor 
45.6% (31 of 68) of the drugs are from USA sponsors, 44.1% (30 of 68) are from European 
sponsors, 3 of them have sponsors from Japan, and the rest 4 have sponsors from other 
regions/countries. 44.1% (30 of 68) of the sponsors are top-sized companies with over 10,000 
employees, while only 2 of them were from small-size businesses. 72.1% (49 of 68) of the 
drugs are from companies that do not have prior experience in orphan drug development. 
Both sponsor nationality and size have shown quasi-complete separation (3 drugs from Japan 
have all been included in NDRL, 2 drugs from small-size sponsors are both included in 
NDRL), so the two variables were not included in the multivariate analysis. The three 
variables related to sponsor are not considered to be associated with reimbursement 
statistically significant.  
 
Discussion 
The analysis of comparing characteristics of orphan drugs approved elsewhere in the world 
(in the US/EU/Japan) to approved ones in China has clarified several determinants associated 
with successful orphan drug approval in China. The analysis of comparing approved and 
reimbursed ones to approved and not reimbursed ones has suggested characteristics of 
successful orphan drug reimbursement in China. Comparing current effective orphan drug 
policies with other countries/regions, mainly in the US, the EU, and Japan will further explain 
these determinants. 
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According to the regression analysis, rare diseases with registered patients in the NRDRS 
have a higher chance of having approved drugs in China. Orphan drugs with bigger sponsors 
have a higher chance of been approved in China. Small molecules rather than biologics have a 
higher chance of been reimbursed.  
 
Determinants for orphan drug approval in China  
Characteristics related to the indication 
Regression analysis indicated that having registration data in NRDRS is associated with 
available rare disease treatment in China. NRDRS is a national rare disease registry. It is part 
of the nation’s rare disease infrastructure, promoted by the National Health Commission, 
funded by the government’s “13th Five-Year Plan” key Research & Development Projects-
Precision Medicine Initiative, and joined by more than 20 top academic institutions in 
China61. The registry began in 2019.11.1, it first retrospectively registered rare disease 
patients diagnosed from 2015.1.1 to 2019.10.31 in member hospitals, and each new case after 
2019 was also required to register62. The ultimate goal of the registry system is to “evaluate 
the diagnosis and treatment standards of rare diseases in China” by conducting standardized 
case registration, cohort identification, and follow-ups of national-wide studies54. Among the 
18 diseases that have registered patients in the system, only four do not have available 
treatments in China yet, including Porphyria, Retinitis Pigmentosa, Langerhans Cell 
Histiocytosis, and Lymphangioleiomyomatosis (LAM)40. Since NRDRS aims to contribute to 
existing knowledge of rare diseases in China and support healthcare policymaking, it might 
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be reasonable to expect that these diseases could have approved drugs in China in the near 
future.  
Higher prevalence of a rare disease is positively associated with orphan drug approval, though 
the result is not considered statistically significant. Despite the fact that different 
countries/regions have defined rare diseases differently based on their prevalence, this might 
suggest that prevalence has played an important role in the regulatory strategies. However, 
measuring the prevalence of rare diseases could be particularly challenging. The data sources 
of rare diseases could be limited and not standardized, so combining the data could be 
difficult. Also, some rare diseases lack diagnostic criteria, so the true prevalence could be 
much underestimated. Besides, it could be challenging from the methodological perspective 
to measure a small sample size63. Even though the prevalence data used in this study might 
not be actual prevalence data of certain diseases, they may still provide important references 
for making regulatory decisions. Previous research from the US has shown that higher 
prevalence is positively associated with approval1. Yet another study in Japan found that the 
number of patients in Japan was negatively associated with approval3. The result from Japan 
might seem counter-intuitive, yet this could be because the number of patients might not be a 
critical criterion when conducting rare disease clinical trials, even randomized and controlled 
trials are not a must3. However, in this study, higher prevalence is numerically positively 
associated with approval. As mentioned before, some drugs are not required to redo clinical 
trials in China, so satisfying medical needs may be prioritized. On the other hand, this 
variable is not statistically significant in the model, so whether it reveals a true association 
should be tested further.  
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Whether having epidemiology studies done in China mainland is another variable that has 
shown a positive association, yet not statistically significant. Generally speaking, lack of 
Chinese data might be a barrier to drug approval. This might also explain why NRDRS is 
critical for decision-making. 
 
Characteristics related to the orphan drug substance 
A previous study in the EU2 showed the lack of an alternative therapy of disease is positively 
associated with new drug approval. This might suggest that the decision-making of EMA 
seems to be driven by satisfying medical needs2. However, the situation in China was 
different. Most of the drugs got approved within a very short period starting in 2018, so 
instead of identifying which diseases have alternative therapies before in China, whether a 
certain disease has multiple treatment methods was measured instead. This study shows that if 
a disease has multiple available treatments on the market, the disease is numerically more 
likely to have approved drugs in China. However, the result is not statistically significant. 
Having alternative therapy or not might be related to the mechanism of certain indications or 
the prevalence of the disease2. In other words, when the cause for a disease is more 
straightforward, more drugs could be developed. Or when the treatment method has the 
potential to treat other diseases with a wider population, pharmaceutical companies would be 
more incentivized to develop drugs, and more drugs are likely to be approved64.  
Due to the limited sample size of each indication category, no data analysis was done. 
However, two studies in the US suggested that approval rates would differ based on 
therapeutic category65,66, so this study might not mean no such association exists. 
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Characteristics related to the prior approval status 
To receive incentives for orphan drugs described above, sponsors must have received an 
orphan designation. Nevertheless, not every country has such process, such as Canada, 
Singapore, and China. In contrast, countries as the US, EU, Japan, and Australia have 
regulations about orphan status recognition67. Different countries have different specific 
criteria, yet generally, they focus on several aspects, including severity and prevalence of the 
disease, non-return on investment, the feasibility of research program, and medical needs. Not 
every drug which has received orphan designation is authorized in the end because it is 
requested at the early stages of drug development, and not every candidate drug would 
complete their clinical development process67,68,69,70,71. A study showed that 64.3% of orphan 
designated drugs in Japan had been approved, which is the highest among the four countries. 
It is only 15.4% in the US and 7% in the EU67. In other words, drugs that apply for orphan 
status in Japan might already have robust drug development evidence67. In general, the orphan 
designation could not be viewed as the guarantee of the safety and efficacy of a drug. It is 
more of the reflection of medical needs and incentives to sponsors. Pharmaceutical companies 
would want to obtain an orphan designation to attract new investors and promote research in 
the future67. In this study, orphan designation seems to be negatively correlated with approval, 
though it is not statistically significant. The result may indicate that at least not every drug 
that has received orphan designation would be considered in priority when approving a drug 
in China. 
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On the other hand, a drug that has received marketing authorization from multiple 
countries/regions is numerically more likely to be approved. The study in Japan shows that 
prior approval in the US is positively correlated with approval in the Japanese market3. 
However, studies in the US and EU showed that such associations between approval 
probability and prior approval status in other countries/regions did not exist because the US 
and EU are the two leading markets1,2,3. Similar in Japan, prior approval status in other 
countries/regions might increase the likelihood of drugs being approved in China. 
 
Characteristics related to the sponsor 
Company size is an essential predictor associated with approval as shown by several previous 
studies. The study in the US showed that small and medium enterprises (less than 250 
employees) are less likely to have orphan drugs approved1. Another study from the EU 
showed that while many university and medical centers or small and medium-sized 
enterprises initiated the early stages of drug development2, it is more likely that larger and 
more experienced companies would eventually sponsor the drugs to the market72,73. This 
study has shown the same result. 
A study in Japan showed that the foreign capital of a company would not impact the approval 
status in Japan3. Similar to this study, the associations between the sponsor’s nationality with 
approval are not statistically significant.  
Previous studies showed that having experience in orphan drug development is an important 
predictor for subsequent approval in the EU and the US1,74. Orphan drug development could 
be more complex than usual drug development. Experienced companies might be more 
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familiar with designing and conducting clinical trials, getting access to patients, and reaching 
out to regulatory departments74. This study also shows that drugs from more experienced 
companies are numerically more likely to be approved, though this result is not statistically 
significant.  
 
Determinants for orphan drug reimbursement in China 
The latest update of NRDL was conducted in 2017. Evidence of Health Technology 
Assessment (HTA) or pharmacoeconomic evaluation were included as essential criteria of 
decision-making76. Also, a pilot project was implemented that the central government would 
negotiate with pharmaceutical companies about the prices for innovative and expensive drugs 
that were still not included in the National Formulary75,76. In other words, drugs that are 
considered clinically valuable but expensive would be put into the price negotiation process 
before officially becoming part of NDRL76. Most of the orphan drugs are considered in this 
category. However, there are uncertainties in the effectiveness, safety and economic 
evaluation process of orphan drugs. Such uncertainties would hinder the access of orphan 
drugs to the medical insurance list37,75. The national government has proposed to set up a 
special procurement project for orphan drugs this year, details yet not been published37. 
This study has not studied the economic side of orphan drugs because their prices would be 
undergoing the negotiation process. However, this is an essential factor determining whether 
a drug could be included in NDRL. Instead, this study focused on characteristics of the drugs 
related to drug type, prior approval status, and the sponsors.  
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This study suggested that among all the characteristics, the type of the drug (i.e., small 
molecule drug or biologics) is of vital importance associated with successful reimbursement. 
Small molecules are produced by chemical synthesis processes with well-defined and stable 
structures. Yet, a biologic is usually a large and complex biomolecule derived from living 
cells or through biological processes with heterogeneous structures. Unlike small molecules, 
biologics are very sensitive to process changes77. Due to the structural complexity of 
biologics, their clinical effects are usually hard to predict77. A previous study in the EU 
showed that small molecule drugs are more likely to get marketing approved than 
biotechnology products2. This could be explained because more knowledge was available for 
small molecules2. While this study does not show that small molecule is associated with a 
higher rate of approval, small molecules are more likely to be included in the NDRL. The 
decision-making criteria of drug reimbursement in China focus on safety, efficacy, clinical 
needs, price and pharmacoeconomic evaluation in other countries, and budget impact62. Small 
molecules may satisfy the requirement for safety than for biologics. Also, from 2015-2019 in 
China, more small molecule drugs have been approved than biotech drugs every year78. 
 
Limitations 
There are some limitations of this study that should be addressed. Clearly, the confidence 
intervals of the association estimations are wide. This could be due to the limited sample size. 
Indication category interaction could not be tested due to the small number of each set. Also, 
some of the explanatory variables are correlated with each other. For example, whether been 
able to receive an orphan designation is associated with the prevalence of the disease. 
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Mechanisms of specific indications may be related to the type of molecules, availability of 
alternative treatments, and applications to other indications. Third, some other possible 
variables are not tested in this study, such as clinical trial characteristics. For example, 
previous studies have shown that positive outcomes of the primary endpoints could be related 
to success approval1. Some orphan drugs could directly use overseas clinical trial data to 
apply for approval, yet some still need new clinical trials been done again in China. Since the 
source of clinical trials are different, and it would be inappropriate to include them in one 
study, so the characteristics of clinical trials are not studied here. However, such variables 
could be further tested and adjusted in the model. Also, some other factors may impact 
whether a drug could be included in NDRL, such as the budget impact on the national 
insurance system79. Future studies could further examine such factors. Fourth, data such as the 
prevalence of rare diseases may not be accurate and complete, as discussed above. Also, prior 
marketing status has only be collected among the US/EU/Japan, and results could be different 
if involving other countries/regions into the analysis. 
 
Summary 
In general, this study has pinpointed two critical characteristics related to orphan drug 
approval in China, and one crucial factor related to orphan drug successful reimbursement in 
China. First, rare diseases that have been registered in the NRDRS have a higher chance of 
having approved drugs in China. Particularly, prevalence and incidence data of most rare 
diseases are still lacking in China and face many challenges of getting the true estimate, so 
having exact registration information in the system is especially critical for policymaking. 
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Drugs from larger-sized companies have higher chances of being approved because the 
orphan drug development process is often more complex and requires more resources. 
Second, small molecule drugs have a higher chance of been included in NDRL than biologics 
because they are more stable in structure and clinical effects. These findings may provide 
information for drug developers and sponsors when submitting applications for orphan drugs 
approval in the near future. The review and approval of orphan drugs have been accelerated 
significantly in China in recent years. Last year, it has been proposed at the National People’s 
Congress and the Chinese People’s Political Consultative Conference that all drugs targeting 
the 121 kinds of rare diseases should be approved and be included in NDRL step by step in 
the future37. However, this process needs continued reform of the healthcare payment system, 
social welfare support, and administrative process. Medical care for rare disease patients now 
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